
PACB Stock Forecast & Price Target
PACB Analyst Ratings
Bulls say
Pacific Biosciences of California Inc. is experiencing positive trends in the placement and utilization of its Revio sequencing platform, which bodes well for its near-term guidance and longer-term growth targets set for 2026. The company has demonstrated a strong organic growth profile while also engaging in strategic acquisitions, indicating a comprehensive approach to expanding its market presence. Despite potential conservatism in guidance due to macroeconomic uncertainties, management's belief in the company's ability to return to growth this year reinforces a favorable outlook for Pacific Biosciences.
Bears say
Pacific Biosciences of California Inc faces a negative outlook primarily due to anticipated stagnation in utilization and demand for its sequencing instruments, which could jeopardize its financial targets for 2026. Additionally, persistent demand weakness, particularly in China, and tightening research budgets pose significant risks to the company's revenue streams. The potential for competitors to develop superior products further exacerbates concerns about market share loss and its consequential impact on Pacific Biosciences's financial performance.
This aggregate rating is based on analysts' research of Pacific Biosciences of California and is not a guaranteed prediction by Public.com or investment advice.
PACB Analyst Forecast & Price Prediction
Start investing in PACB
Order type
Buy in
Order amount
Est. shares
0 shares